Two of the most cited repair-model peptides, compared on sequence origin, the tissue models each appears in, and how laboratories typically design studies around them.
At a glance
- BPC-157: a synthetic 15-amino-acid sequence derived from a fragment of human gastric juice protein BPC.
- TB-500: a synthetic peptide corresponding to the active region of the naturally occurring protein thymosin beta-4.
- Both appear in repair and remodelling literature, but they enter that literature from different biological starting points.
- Both are supplied here as lyophilised powders at ≥99% HPLC purity with a batch-matched certificate of analysis.
Sequence origin and structure
BPC-157 is a pentadecapeptide — fifteen residues — described in the literature as a stable gastric pentadecapeptide. It has no direct natural analogue in circulation; it is a defined synthetic sequence taken from a larger protective protein found in gastric juice, and it is notable in published work for its stability in aqueous conditions relative to many short peptides.
TB-500 is shorter and functions as a fragment rather than a full protein. Thymosin beta-4 is a 43-residue actin-binding protein present in most mammalian cells; TB-500 reproduces the region associated with actin binding, which is why the two names are often used interchangeably in laboratory writing even though they are not the same molecule.
Pathways described in the literature
Published BPC-157 work tends to cluster around angiogenic signalling, growth-factor receptor expression and the nitric oxide system, often in gastrointestinal, tendon and soft-tissue injury models.
TB-500 literature is dominated by actin sequestration: by binding G-actin it influences cytoskeletal assembly, and downstream of that, cell migration models. Endothelial migration and wound-closure assays are the typical experimental setting.
The practical distinction for study design is that BPC-157 papers usually measure signalling and vascular endpoints, while TB-500 papers usually measure cell motility and structural endpoints. Investigators comparing the two in one model commonly select endpoints that can capture both.
Handling and laboratory characteristics
- Both arrive lyophilised and should be stored sealed at -20°C, protected from light, and allowed to reach room temperature before opening.
- Both reconstitute readily in bacteriostatic or sterile water added slowly down the vial wall, with gentle swirling and no shaking.
- TB-500 is frequently supplied and studied in larger nominal quantities than BPC-157, which affects working concentration planning.
- Once in solution, both should be treated as short-dated: refrigerate, minimise septum entries and prepare fresh where an endpoint is concentration-sensitive.
How laboratories usually choose between them
Selection is normally driven by the model rather than by any ranking of the two compounds. Work centred on vascular response, growth-factor expression or gastrointestinal tissue tends to cite BPC-157. Work centred on migration, cytoskeletal dynamics or epithelial closure tends to cite TB-500.
The two are also studied together, and a blended reference preparation is available for laboratories running combined repair models where both pathways are of interest.
Whichever is selected, the analytical basis should match: confirm purity, identity and batch code on the certificate before the first experiment, and keep the certificate with the study record.